ARCHIVES

“Spoiled, Petulant Brat”: BioMarin CEO Fires Off Feisty Emails In Battle Over Access to PARP Inhibitor

This article is from The Cancer Letter archive.

Vol. 39 No. 42 | November 8, 2013

Download PDF Visit The Full Archive

Related Articles

NIH Programs: Advisory Panel Formed On Cancer and Alternative Medicine

July 16, 1999

False-Positive Mammograms Can Indicate Higher Cancer Risk

April 27, 2012

Officals: “Separations” in Normal Range as Critics Claim Brain Drain in the Clinic

January 17, 2014

Tobacco Company Liggett Gave $3.6 Million To Henschke For CT Screening Research.

March 28, 2008

Center And Cooperative Group Clinical Trials Approved By NCI

May 27, 2005

DCE Board Approves Concept For studies Of Thorotrast Exposure

November 16, 1990